Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20400 participants
OBSERVATIONAL
2021-10-23
2022-08-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Epigenetics and NCD Prevention in Kazakhstan: Personalized Approaches and Biological Age Prediction
NCT06953180
Risk Factors at Chronic Non-communicable Diseases in People of Working Age
NCT06812767
Prevention of NCDs Through Screening and Educating Individuals on Health-risk Behaviours in the Community
NCT05790395
Rural Chronic Disease Risk Reduction
NCT05611580
Effect of Motivational Interviews on Cardiovascular Disease Risks and Healthy Lifestyle Behavior Changes
NCT05390931
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
The study Group
Population of Kazakhstan
Blood test
Glucose Glycosylated hemoglobin Triglycerides Total cholesterol HDL Cholesterol LDL Cholesterol Creatinine COVID-19 Antibody IgM to N protein SARS-Cov-2 (Abbott) COVID-19 Antibody IgG to N protein SARS-Cov-2 (Abbott)
STEPwise Approach to NCD Risk Factor Surveillance (STEPS)
The WHO STEPwise Approach to NCD Risk Factor Surveillance (STEPS) is a simple, standardized method for collecting, analysing and disseminating data on key NCD risk factors in countries. The survey instrument covers key behavioral risk factors: tobacco use, alcohol consumption, physical activity, unhealthy diet, as well as key biological risk factors: overweight and obesity, raised blood pressure, raised blood glucose, and abnormal blood lipids. Through the use of expanded modules, the survey instrument can be expanded to cover a range of topics beyond these risk factors, such as oral health, sexual health and road safety.
Spirometry
Spirometry is a common office test used to assess how well your lungs work by measuring how much air you inhale, how much you exhale and how quickly you exhale.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood test
Glucose Glycosylated hemoglobin Triglycerides Total cholesterol HDL Cholesterol LDL Cholesterol Creatinine COVID-19 Antibody IgM to N protein SARS-Cov-2 (Abbott) COVID-19 Antibody IgG to N protein SARS-Cov-2 (Abbott)
STEPwise Approach to NCD Risk Factor Surveillance (STEPS)
The WHO STEPwise Approach to NCD Risk Factor Surveillance (STEPS) is a simple, standardized method for collecting, analysing and disseminating data on key NCD risk factors in countries. The survey instrument covers key behavioral risk factors: tobacco use, alcohol consumption, physical activity, unhealthy diet, as well as key biological risk factors: overweight and obesity, raised blood pressure, raised blood glucose, and abnormal blood lipids. Through the use of expanded modules, the survey instrument can be expanded to cover a range of topics beyond these risk factors, such as oral health, sexual health and road safety.
Spirometry
Spirometry is a common office test used to assess how well your lungs work by measuring how much air you inhale, how much you exhale and how quickly you exhale.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
69 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Asfendiyarov Kazakh National Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ildar Fakhradiyev
Head of the Laboratory of Experimental Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Timur M Saliev
Role: PRINCIPAL_INVESTIGATOR
S.D. Asfendiyarov Kazakh National Medical University
Ildar Fakhradiyev, PhD
Role: STUDY_CHAIR
S.D. Asfendiyarov Kazakh National Medical University
Mukhtar B Kulimbet, MD/MSc
Role: STUDY_DIRECTOR
S.D. Asfendiyarov Kazakh National Medical University
Zhumaly A Kauyzbay, PhD, AP
Role: PRINCIPAL_INVESTIGATOR
Joint Stock Company - South Kazakhstan Medical Academy
Samat S Saparbayev, PhD
Role: PRINCIPAL_INVESTIGATOR
West Kazakhstan Marat Ospanov Medical University
Alma U Nurtazina, MD/PhD
Role: PRINCIPAL_INVESTIGATOR
NCJSC Semey Medical University
Bayan A Ainabekova, MD/DMSc
Role: PRINCIPAL_INVESTIGATOR
NCJSC Astana Medical University
Anar A Turmukhambetova, DMSc
Role: PRINCIPAL_INVESTIGATOR
NCJSC Karaganda Medical University
Maksut K Kulzhanov, DMSc
Role: PRINCIPAL_INVESTIGATOR
Kazakhstan's Medical University "KSPH"
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kazakhstan
Almaty, , Kazakhstan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Baspakova A, Abitova AZ, Mussin NM, Kaliyev AA, Yerimbetova G, Zhumagaliyeva S, Ashimova Z, Zhilisbayeva KR, Umbetova AA, Nurtazina AU, Tamadon A. Sex differentials in the prevalence of behavioral risk factors and non-communicable diseases in adult populations of West Kazakhstan. Front Public Health. 2024 Feb 14;12:1333887. doi: 10.3389/fpubh.2024.1333887. eCollection 2024.
Nursultanova L, Kabulbayev K, Ospanova D, Tazhiyeva A, Datkhayev U, Saliev T, Tanabayeva S, Fakhradiyev I. Prevalence of chronic kidney disease in Kazakhstan: evidence from a national cross-sectional study. Sci Rep. 2023 Sep 7;13(1):14710. doi: 10.1038/s41598-023-42031-2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1197
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.